3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Advanced Solid Tumors
4
Triple Negative Metastatic Breast Cancer
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Childhood Solid Tumors
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Tumor
1
Advanced Ovarian Cancer
1
Interventions
Injections
26
toripalimab
17
pembrolizumab
17
tislelizumab
12
Gemcitabine
8
Cisplatin
7
spartalizumab
6
atezolizumab
6
Irinotecan
6
Carboplatin
6
Paclitaxel
5
Oxaliplatin
5
Nivolumab
5
Leucovorin
5
Fluorouracil
5
camrelizumab
4
Pemetrexed
4
Docetaxel
4
Cetuximab
4
Capecitabine
4
trastuzumab deruxtecan
3
sintilimab
3
olaparib
3
lenvatinib
3
cediranib
3
PM 01183
3
Drug Therapy
3
Cyclophosphamide
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Solid Tumor
×
talazoparib
×
Other solid neoplasm
×
Clear all
NCT04497116
2025-10-21
TRESR
Repare Therapeutics
Phase 1/2
Completed
276 enrolled
33 charts